A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis

A Multi-site, Open-Label study of Patient Perception and Quality of Life Associated with the
use of Olopatadine 0.2% in Subjects with Allergic Conjunctivitis. The concentration of
olopatadine in this formulation (PATADAY TM) is 0.2%. PATADAY TM has been approved and is
marketed in India for the once-daily treatment of ocular itching associated with allergic
conjunctivitis.

Hence, the objective of the current study is to evaluate subject perceptions of olopatadine
0.2%, dosed once-daily, in subjects with allergic conjunctivitis and to record any adverse
events as described by the patients as a part of this post marketing surveillance study.